sonnet biotherapeutics is an early stage company developing a pipeline of bifunctional therapies that attack immune-modulating targets to control cancer cells. sonnet biotherapeutics is utilizing a platform approach to develop a library of cancer-fighting immunotherapies. sonnet is based in cranbury, new jersey. sonnet mission: sonnet biotherapeutics is a platform enabled proof-of-concept engine created to generate immuno-oncology candidates and develop them into phase ii assets. we are leveraging a unique ip driven platform: ● single chain platform with pk enhancement ● selectively targeting tumors and their micro-environment ● validated targets only ● dual targeting can create synergies
Company profile
Ticker
SONN
Exchange
Website
CEO
Michael Pruitt
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Chanticleer Holdings, Inc., TULVINE SYSTEMS INC
SEC CIK
Corporate docs
Subsidiaries
Sonnet BioTherapeutics, Inc. • Sonnet BioTherapeutics CH SA • SonnetBio Pty Ltd ...
IRS number
522102141
SONN stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
11 Mar 24
8-K
Other Events
6 Mar 24
8-K
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update
14 Feb 24
10-Q
2024 Q1
Quarterly report
14 Feb 24
8-K
Other Events
1 Feb 24
8-K
Other Events
29 Jan 24
EFFECT
Notice of effectiveness
5 Jan 24
CORRESP
Correspondence with SEC
3 Jan 24
UPLOAD
Letter from SEC
29 Dec 23
8-K
Departure of Directors or Certain Officers
27 Dec 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 23 | Sep 22 | Sep 21 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
1.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 10 |
Opened positions | 2 |
Closed positions | 15 |
Increased positions | 1 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 55.16 mm |
Total shares | 38.28 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Renaissance Technologies | 19.05 k | $55.00 k |
Vanguard | 14.63 k | $41.90 mm |
UBS UBS Group AG - Registered Shares | 3.71 k | $10.64 mm |
BLK Blackrock | 594.00 | $1.70 mm |
MS Morgan Stanley | 142.00 | $407.00 k |
BAC Bank Of America | 94.00 | $270.00 k |
Advisor | 45.00 | $129.00 k |
WFC Wells Fargo & Co. | 11.00 | $32.00 k |
IFP Advisors | 6.00 | $17.00 k |
C Citigroup | 3.00 | $9.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Oct 23 | Raghu Rao | Common Stock | Buy | Acquire P | No | No | 0 | 15,625 | 0.00 | 16,813 |
27 Oct 23 | Raghu Rao | Warrant to Purchase Common Stock Common Stock | Buy | Acquire P | No | No | 1.6 | 31,250 | 50.00 k | 31,250 |
27 Oct 23 | Mohan Pankaj | Common Stock | Buy | Acquire P | No | No | 0 | 34,375 | 0.00 | 59,526 |
27 Oct 23 | Mohan Pankaj | Warrant to Purchase Common Stock Common Stock | Buy | Acquire P | No | No | 1.6 | 68,750 | 110.00 k | 68,750 |
14 Jun 23 | Susan Dexter | Common Stock | Buy | Acquire P | No | No | 0.7 | 10,000 | 7.00 k | 33,667 |
30 May 23 | Dyrness Albert D. | Common Stock | Buy | Acquire P | No | No | 0.468 | 23,255 | 10.88 k | 28,962 |
News
Sonnet BioTherapeutics Announces A Publication Demonstrating Safety And Tolerability Of SON-1010 In Healthy Volunteers
29 Feb 24
Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $30
15 Feb 24
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
14 Feb 24
Sonnet BioTherapeutics Q1 EPS $(0.31) May Not Be Comparable To $(0.90) Estimate, Sales $18.63K Beat $18.00K Estimate
14 Feb 24
12 Health Care Stocks Moving In Tuesday's After-Market Session
13 Feb 24
Press releases
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
19 Mar 24
Sonnet BioTherapeutics Announces Early Safety Data from the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study's Initial Pre-Specified Objective
11 Mar 24
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update
14 Feb 24